Anti-Infective Drugs Market By Drug Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Anti-Infective Drugs Market
Anti-Infective Drugs Market: By Drug Type (Antifungals, Antibacterials and Antivirals); By Infection Type(HIV, Hepatitis B, Hepatitis C, Urinary Tract, Respiratory Candidiasis, and Others); and By Geography (Europe, APAC, North America, ROW) –Forecast (2016-2021)
Report Code : HCR 0149
Updated Date: 25 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Anti-Infective Drugs – Market Overview
2. Executive Summary
3. Anti-Infective Drugs Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Anti-Infective Drugs – Market Forces
   4.1. Drivers
      4.1.1. Increasing number of patients pool globally
      4.1.2. Increasing drug approval
   4.2. Restraints
      4.2.1. Possible side effects over a long term
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Anti-Infective Drugs Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Anti-Infective Drugs Market, By Drugs Type
   6.1. Antifungals
      6.1.1. Allylamines
      6.1.2. Azoles
      6.1.3. Polyene Macrolides
      6.1.4. Other Antifungals Diuretics
   6.2. Antibacterials
      6.2.1. Aminoglycosides
      6.2.2. Carbapenems
      6.2.3. Cephalosporins
      6.2.4. Macrolides
      6.2.5. Penicillins
      6.2.6. Quinolones
      6.2.7. Sulfonamides
      6.2.8. Tetracyclines
      6.2.9. Others Calcium channel blockers
   6.3. Antivirals
      6.3.1. Nucleoside Analogs
      6.3.2. Transcriptase Inhibitors
      6.3.3. DNA Polymerase Inhibitors
      6.3.4. Protease Inhibitors
      6.3.5. Other Antivirals Angiotensin-converting enzyme (ACE) inhibitors
7. Anti-Infective Drugs Market, By Infection
   7.1. HIV
   7.2. Hepatitis B
   7.3. Hepatitis C
   7.4. Urinary Tract
   7.5. Respiratory Candidiasis
   7.6. Other Infections
8. Anti-Infective Drugs Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Anti-Infective Drugs – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles
   10.1. Abbott Laboratories
      10.1.1.  Introduction
      10.1.2. Financials
      10.1.3. Key Insights
      10.1.4. Key Strategy
      10.1.5. Product Portfolio
      10.1.6. SWOT Analysis
   10.2. Alcon Pharmaceuticals Ltd.  
      10.2.1. Introduction
      10.2.2. Financials
      10.2.3. Key Insights
      10.2.4. Key Strategy
      10.2.5. Product Portfolio
      10.2.6. SWOT Analysis
   10.3. Astellas Pharma Inc.   
      10.3.1.  Introduction
      10.3.2. Financials
      10.3.3. Key Insights
      10.3.4. Key Strategy
      10.3.5. Product Portfolio
      10.3.6. SWOT Analysis
   10.4. AstraZeneca Plc     
      10.4.1. Introduction
      10.4.2. Financials
      10.4.3. Key Insights
      10.4.4. Key Strategy
      10.4.5. Product Portfolio
      10.4.6. SWOT Analysis
   10.5. Bayer HealthCare AG    
      10.5.1. Introduction
      10.5.2. Financials
      10.5.3. Key Insights
      10.5.4. Key Strategy
      10.5.5. Product Portfolio
      10.5.6. SWOT Analysis
   10.6. Bristol-Myers Squibb Co.    
      10.6.1. Introduction
      10.6.2. Financials
      10.6.3. Key Insights
      10.6.4. Key Strategy
      10.6.5. Product Portfolio
      10.6.6. SWOT Analysis
   10.7. Boehringer Ingelheim  
      10.7.1. Introduction
      10.7.2. Financials
      10.7.3. Key Insights
      10.7.4. Key Strategy
      10.7.5. Product Portfolio
      10.7.6. SWOT Analysis
   10.8. Sanofi-Aventis SA     
      10.8.1. Introduction
      10.8.2. Financials
      10.8.3. Key Insights
      10.8.4. Key Strategy
      10.8.5. Product Portfolio
      10.8.6. SWOT Analysis
   10.9. Novartis AG
      10.9.1. Introduction
      10.9.2. Financials
      10.9.3. Key Insights
      10.9.4. Key Strategy
      10.9.5. Product Portfolio
      10.9.6. SWOT Analysis
   10.10. GlaxoSmithKline Plc     
      10.10.1. Introduction
      10.10.2. Financials
      10.10.3. Key Insights
      10.10.4. Key Strategy
      10.10.5. Product Portfolio
      10.10.6. SWOT Analysis
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Anti-infective drugs can be defined as drugs which are capable of killing an infectious agent or inhibit it from spreading and are used for the purpose of killing and/or suppressing the infection causing organisms from invading the host organism by means of its replication or releasing variety of toxins in the host. Such infection causing micro-organisms include viruses, bacteria, fungi, viroids and macro parasites. This report is focused on identifying market size for anti-infective drugs globally. Increasing patient pool globally is one of the major drivers for the growth of the anti-infective drugs coupled with increasing R&D activities and increasing approval for new drugs.

This report identifies the anti-infective drugs market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to anti-infective drugs market.

Anti-Infective Drugs Market

Globally North America dominated market for anti-infective drugs in 2015 due to higher awareness about migraine and its effects and is estimated to continue the same during the period of study. North America was followed by Europe and Asia-Pacific as the second and third largest markets respective in 2015. Demand for anti-infective drugs in the Asia-Pacific region is estimated to be grow fastest during the period of study and is expected to be driven by large population pool, government initiatives of undertaking various control programs and private partnership projects and rising cost containment initiatives by drug manufacturers. This report on global anti-infective drugs also covers different classes of anti-infective drugs available and market size in various geographical regions.
  • On the basis of anti-infective drug type this report classifies as follows covering all major types of drugs available in the market: Antifungals (Allylamines, Azoles, Polyene Macrolides and Other Antifungals Diuretics), Antibacterials (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines and Others Calcium channel blockers), Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors and Other Antivirals Angiotensin-converting enzyme (ACE) inhibitors)
  • This report on global anti-infective drugs is also classified on the basis of infection type covering all major types of infections as follows: HIV, Hepatitis B, Hepatitis C, Urinary Tract, Respiratory Candidiasis and Other Infections
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for anti-infective drugs in each of the region.

Sample Companies Profiled in this Report are: 

  • Abbott Laboratories
  • Alcon Pharmaceuticals Ltd.  
  • Astellas Pharma Inc.   
  • AstraZeneca Plc     
  • Bayer HealthCare AG
  • 10+
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports